[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto do Cancer do Estado de São Paulo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":586},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,46,75,105,128,148,233,267,306,333,363,389,414,435,460,488,513,538,564],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643356","safety-and-performance-evaluation-of-the-ronovotm-robotic-surgical-platform-in-oncological-procedures-100643356",false,"NCT07632638","Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures","Safety and Technical Evaluation of a Robotic Platform (RonovoTM) in Elective Oncological Surgery: A Prospective, Single-Arm, Multi-Specialty Registry","CONSTELAR","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Confirmed malignancy diagnosis\n3. Elective indication for robotic approach using RonovoTM\n4. Able to understand and sign informed consent\n\nExclusion Criteria:\n\n1. Formal contraindication to minimally invasive surgery\n2. Severe comorbidity prohibiting the procedure\n3. Refusal to participate or sign informed consent\n4. Emergency surgery","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","CONSTELAR is a prospective, single-arm, multi-specialty registry designed to evaluate the safety and intraoperative performance of the RonovoTM robotic surgical platform in adult patients undergoing elective oncological surgery. The study enrolls patients across four surgical specialties (Digestive Surgery, Thoracic Surgery, Urology, and Gynecology) at a single academic center. Primary endpoints include 30-day and 90-day complication rates (Clavien-Dindo classification), operative times, conversion rates, estimated blood loss, and device-related technical failures. Secondary endpoints encompass length of hospital stay, Intensive Care Unit (ICU) admission, readmission\u002Freoperation rates, and oncological surgical outcomes (resection margins, lymph node harvest). The study aims to provide initial safety and feasibility data to support the regulatory pathway for the RonovoTM platform in Latin America.",[27,28],"Malignant Neoplasms","Cancer",[30,31,32],"Robotic surgery","Minimally invasive surgery","Oncological surgery","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-06-19",{"date":41,"type":21},"2026-12",{"name":43,"class":44},"Instituto do Cancer do Estado de São Paulo","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100598019","artificial-intelligence-assisted-colonoscopy-in-the-detection-and-characterization-of-colorectal-lesions-100598019","NCT07066046","Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions","Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions: Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* All patients aged 18 years or older, with an elective indication for colonoscopy who sign the informed consent form agreeing to participate in the study.\n\nExclusion Criteria:\n\n* History of inflammatory bowel disease.\n* History of colorectal cancer.\n* Personal history of colorectal surgery.\n* Contraindication to endoscopic biopsies.\n* History of intestinal polyposis syndromes.\n* Urgent or emergency cases.\n* Presence of severe, decompensated comorbidities, or with a score of 3 or higher according to the American Society of Anesthesiologists (ASA) classification.\n* Incomplete colonoscopy that does not reach the cecum.\n* Insufficient or inadequate bowel preparation, with a score lower than 6 on the Boston Bowel Preparation Scale.\n* Patients who do not agree to participate in the study and do not sign the informed consent form (ICF).",true,{"count":55,"type":21},1000,[24],"The study aims to evaluate the effectiveness of artificial intelligence-assisted colonoscopy in increasing adenoma detection rate and the accuracy in the characterization of colorectal lesions, compared to standard colonoscopy, in a randomized controlled clinical trial setting.",[59,60,61,62],"Colorectal Cancer (CRC)","Adenomatous Polyposis","Colorectal Lesions","Colorectal Cancer",[64,65,66,67],"Adenoma","Artificial Intelligence","Colonoscopy","Colorectal lesions",{"date":69,"type":37},"2026-06-23",{"date":71,"type":37},"2025-02-01",{"date":73,"type":21},"2026-12-01",{"name":43,"class":44},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":45},"100642735","percutaneous-biopsy-after-neoadjuvant-chemotherapy-100642735","NCT07644455","Percutaneous Biopsy After Neoadjuvant Chemotherapy.","Evaluation of the Accuracy of Vacuum-assisted Percutaneous Biopsy in Predicting Mammary Anatomopathological Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","VAC-Biopsy","Inclusion Criteria:\n\n* Female patients with invasive non-special type mammary carcinoma (any immunohistochemical subtype: luminal, triple-negative, or HER2+)\n* Indication for neoadjuvant chemotherapy\n* Tumor clipping performed prior to neoadjuvant chemotherapy\n* Clinical staging cT1-T3, N0-N1, M0, defined by clinical examination, mammography, breast MRI, chest\u002Fabdomen\u002Fpelvis CT, and bone scintigraphy\n* Complete clinical and imaging response OR residual lesion ≤2 cm in largest diameter on mammography and MRI after neoadjuvant chemotherapy and before surgical treatment\n\nExclusion Criteria:\n\n* Multicentric tumors (\\> 2 lesions)\n* Current use of anticoagulants\n* Extensive calcifications (\\> 2 cm)\n* Pregnant women\n* Not undergoing surgical treatment\n* Personal history of other malignancies in the last 5 years\n* Absence of residual lesion on imaging in cases of clip migration from the tumor bed marking","FEMALE",{"count":85,"type":21},100,[24],"Neoadjuvant chemotherapy is widely used in the treatment of locally advanced breast cancer or in early stages of triple-negative or HER2 overexpressing tumors. Pathological complete response (pCR) to neoadjuvant chemotherapy is associated with better clinical outcomes. However, confirmation of pCR still depends on surgery, which may represent overtreatment for some patients. In this context, image-guided vacuum-assisted percutaneous biopsy (VAB) has been investigated as an alternative to assess tumor response and potentially avoid breast surgery in the future. However, there are no studies evaluating this strategy in brazilian patients, the majority of whom present with locally advanced tumors at diagnosis.",[89],"Breast Cancer",[91,92,93,94,95,96],"Breast cancer","Neoadjuvant chemotherapy","Percutaneous biopsy","Vacuum-assisted biopsy","Pathological complete response","Conservative surgery","NOT_YET_RECRUITING","2026-06-08",{"date":100,"type":37},"2026-06-12",{"date":102,"type":21},"2026-06",{"date":41,"type":21},{"name":43,"class":44},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100637623","evaluation-of-persistent-infection-by-oncogenic-human-papillomavirus-hpv-in-patients-treated-for-cervical-carcinoma-and-its-relation-to-prognostic-factors-100637623","NCT07600515","Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors","ANIHTA","Inclusion Criteria:\n\n* Diagnosis of HPV-associated squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma\n* Treatment-naïve\n* FIGO 2018 stage IB3 to IVA\n* Candidates for curative-intent pelvic radiotherapy with concurrent chemoradiation\n\nExclusion Criteria:\n\n* Tumors with rare histology, such as small cell tumors, sarcomas, and lymphomas\n* FIGO 2018 stages IA, IB1, IB2, and IVB\n* Planned initial treatment is surgical or palliative\n* Uncertain primary tumor site (cervix vs. endometrium)\n* Pregnant or in the postpartum period\n* Immunosuppression (e.g., HIV infection with active disease, autoimmune diseases, transplant recipients)",{"count":85,"type":21},"OBSERVATIONAL","Cervical cancer is strongly associated with HPV infection, yet current post-treatment follow-up relies on cytology and imaging, which have limited accuracy, particularly after radiotherapy. Emerging evidence suggests that HPV clearance is linked to better outcomes and that HPV testing may outperform cytology in detecting recurrence.\n\nThis study aims to evaluate a panel of prognostic biomarkers to identify patients at higher risk of recurrence. These include cervical and circulating HPV-DNA (presence, genotype, and load), vaginal microbiota, host DNA methylation, SOD2 expression, and immune profile.\n\nBy enabling earlier and more accurate detection of recurrence, these biomarkers may improve patient outcomes, reduce reliance on costly imaging, and support earlier discharge for low-risk patients.",[116,117],"Locally Advanced Cervical Cancer","Prognostic Biomarker",[119],"Cervical cancer recurrent or persistent","2026-06-02",{"date":122,"type":37},"2026-06-03",{"date":124,"type":21},"2026-05-10",{"date":126,"type":21},"2030-05-10",{"name":43,"class":44},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":134,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":147,"locationsCount":45},"100617289","phase-1-phase-i-study-of-docetaxel-and-177-lutetium-psma-it-in-first-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-adenocarcinoma-100617289","NCT07316686","Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma","Inclusion Criteria:\n\n1. Men aged 18 years or older.\n2. Histological or cytological diagnosis of prostate adenocarcinoma. The presence of intraductal or cribriform carcinoma will be allowed.\n3. Presence of metastatic disease on conventional imaging exams (bone scintigraphy and\u002For CT scan or MRI).\n4. Patients with castration-resistant disease, defined as testosterone \\\u003C50 ng\u002FmL in the context of prior orchiectomy or ongoing androgen deprivation therapy (ADT) with LHRH agonists or antagonists, plus at least one of the criteria below:\n5. PSA ≥2.0 ng\u002FmL with at least two consecutive PSA rises at intervals of at least 1 week.\n6. Radiologic progression defined by the investigator.\n7. Clinical progression defined by the investigator.\n8. Performance status per the Eastern Cooperative Oncology Group (ECOG) equal to 0 or 1.\n9. Willingness to continue ongoing ADT.\n10. Adequate organ function as defined below:\n\n    * Parameter Requirement\n    * Neutrophils ≥ 1,500\u002FµL\n    * Hemoglobin ≥ 12 g\u002FdL\n    * Platelets ≥ 100,000\u002FµL\n    * Creatinine ≤ 1.5 x upper limit of normal\n    * Potassium \\> 3.5 mmol\u002FL and \\\u003C5.0 mmol\u002FL\n    * Total Bilirubin ≤ ULN (unless Gilbert's disease)\n    * AST (TGO) ≤ 2.5 x ULN\n    * ALT (TGP) ≤ 2.5 x ULN\n11. 68Ga-PSMA-PET\u002FCT performed during the screening phase showing metastatic (extraprosthetic and extrapelvic) disease with radiotracer uptake and:\n12. SUVmax ≥20 in at least one site;\n13. SUVmax \\>10 in all other measurable metastatic sites.\n14. Lesions with uptake at least 1.5 times greater than hepatic background will be considered measurable.\n\nExclusion Criteria:\n\n1. Presence of any small-cell or neuroendocrine component of prostate carcinoma.\n2. Prior receipt of chemotherapy or radiopharmaceuticals in the castration-resistant setting.\n3. Presence of another active malignancy requiring treatment or a cancer diagnosis within the past 5 years. Carcinoma in situ of any site, squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or papillary bladder tumors will be allowed if previously treated.\n4. Severe urinary incontinence at the investigator's discretion.\n5. 18F-FDG-PET\u002FCT will be performed during screening and will be considered exclusionary if there is discordance with the 68Ga-PSMA-PET\u002FCT. Discordance is defined as FDG-hypermetabolic lesions with absent or low PSMA uptake (SUVmax \\\u003C10) in more than 50% of measurable metastatic lesions.\n6. Patients with brain metastases visible on 68Ga-PSMA-PET\u002FCT.","MALE",{"count":136,"type":21},18,[138],"PHASE1","This is a Phase I, open-label, single-center study evaluating the safety, tolerability, and recommended Phase II dose of docetaxel when combined with a fixed dose of 177-Lutetium-PSMA-I\\&T in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). Patients will receive standard androgen deprivation therapy, docetaxel at escalating doses (50 mg\u002Fm², 60 mg\u002Fm², 75 mg\u002Fm² every 3 weeks), and 177Lu-PSMA-I\\&T at a fixed dose of 7.4 GBq every 6 weeks (up to 4 cycles). A 3+3 dose escalation design will be employed. Secondary endpoints include safety profile, treatment-limiting toxicities, treatment completion rate, and delayed toxicity. Exploratory endpoints include PSA response, radiographic progression-free survival (rPFS), and PERCIST-based response rate.",[141],"Prostate Cancer (Adenocarcinoma)","2026-05-14",{"date":144,"type":37},"2026-05-18",{"date":102,"type":21},{"date":41,"type":21},{"name":43,"class":44},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":160,"conditions":161,"keywords":203,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100565188","phase-2-agnostic-therapy-in-rare-solid-tumors-100565188","NCT06638931","Agnostic Therapy in Rare Solid Tumors","Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors","ANTARES","Inclusion Criteria\n\n1. Age 18 years or older.\n2. Patients with immunohistochemistry for PD-L1 with a combined positive score (CPS) of 10 or higher.\n3. Patients with progression or intolerance to already approved and accessible treatments for the specific neoplasm and population.\n4. Documented disease progression radiologically after the last routine treatment.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy can only be used as target lesions if they are confirmed to be progressing by imaging before enrollment.\n7. Male participants must meet at least one of the following conditions:\n\n   1. Considered infertile;\n   2. No fertile partner;\n   3. Has a fertile partner who agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab;\n\n      and\n   4. Agrees to abstain from sperm donation throughout the study period and for at least 6 months after the last dose of Nivolumab.\n8. Female participants must meet at least one of the following conditions:\n\n   1. Considered infertile;\n   2. Agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab;\n9. Estimated life expectancy greater than 12 weeks, as determined by the investigator or delegated sub-investigator.\n10. Preserved organ functions defined by:\n\n    * Absolute neutrophil count ≥ 1,000;\n    * Hemoglobin ≥ 8.0 g\u002FdL (patients may receive transfusions to reach this level);\n    * Platelet count ≥ 100,000;\n    * Total bilirubin ≤ 1.5 × Upper Limit of Normal (ULN), or ≤ 3.0 × ULN for patients with Gilbert's syndrome;\n    * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN in the presence of liver metastases);\n    * Creatinine clearance \\> 30 mL\u002Fmin (estimated by Cockcroft-Gault).\n11. Diagnosis of rare cancer (List I) confirmed by histopathological examination, with the possibility of including other types of rare tumors (incidence of less than 6 in every 100,000) after careful evaluation and approval by the study board.\n\n    * List I:\n\n      * Urachal adenocarcinoma\n      * Parathyroid carcinoma\n      * Nasopharyngeal epithelial tumors\n      * Fibrolamellar carcinoma of any primary site\n      * Angiosarcoma of any primary site\n      * Secretory breast carcinoma\n      * Anal cancer\n      * Metaplastic breast carcinoma\n      * Chromophobe renal carcinoma, Microphthalmia-associated Transcription Factor (MiT) family translocation renal carcinoma; renal carcinoma with Fumarate Hydratase (FH) or Succinate Dehydrogenase (SDH) deficiency\n      * Carcinosarcoma of any primary site\n      * Small intestine cancer\n      * Cholangiocarcinoma\n      * Sertoli-Leydig cell tumors\n      * Cervical cancer of non-epidermoid histology\n      * Tracheal epithelial tumors\n      * Non-cystadenoma salivary gland tumors\n      * Mesothelioma of any site\n      * Neuroblastoma\n      * Adrenal cancer\n      * Penile cancer\n      * Apocrine carcinoma\n      * Fibrosarcoma of any primary site\n      * Cancer of unknown primary site\n      * Hemangioblastoma of any primary site\n      * Thyroid cancer\n      * Hepatoblastoma\n      * Fallopian tube cancer\n      * Leiomyosarcoma of any primary site\n      * Vaginal cancer\n      * Neurofibrosarcoma of any primary site\n      * Gallbladder cancer\n      * Osteosarcoma of any primary site\n      * Bile duct cancer\n      * Clear cell endometrial carcinoma\n      * Yolk sac tumor of any primary site\n      * Non-epidermoid bladder cancer\n      * Vulvar cancer\n      * Kaposi's sarcoma\n      * Epithelial ovarian cancer\n      * Soft tissue sarcoma\n      * Urethral cancer\n      * Granulosa cell tumor of any primary site\n      * Cystadenoma carcinoma\n      * Primitive neuroectodermal tumor of any primary site\n      * Pure or mixed neuroendocrine tumors with neuroendocrine component\n      * Trophoblastic tumor\n\nExclusion Criteria\n\n1. Previous treatment lines with immunotherapy (immune checkpoint inhibitors).\n2. Pregnant or breastfeeding individuals.\n3. Limiting comorbidity, in the opinion of the investigator.\n4. Active infection.\n5. Major surgery within the last 4 weeks.\n6. Functional class II or greater heart failure.\n7. Myocardial infarction or stroke within the last 6 months.\n8. History of pulmonary fibrosis or pneumonitis.\n9. Autoimmune diseases, except for patients with vitiligo and\u002For controlled thyroid\u002Fhypothyroidism without the use of immunosuppressors.\n10. Second invasive primary tumor diagnosed in the last 3 years and\u002For with active disease, except for localized skin tumors (non-melanoma) that have been treated with curative intent.\n11. Patients with prolonged QT interval.\n12. Uncontrolled Central Nervous System (CNS) metastases. Patients who have previously received local treatment, such as radiotherapy, will be eligible if clinical and radiological stability is demonstrated in the 2 weeks prior to the start of treatment. Patients must not be using corticosteroids for managing CNS disease.\n13. Presence of meningeal carcinomatosis.\n14. Worsening renal and liver function in the 14 days prior to enrollment.\n15. History of solid organ transplantation with or without immunosuppression.\n16. Patients with untreated acquired immunodeficiency. Immunocompromised patients may be included as long as they do not have active opportunistic disease and\u002For active infection, after thorough clinical evaluation by the investigator or sub-investigator. HIV-positive patients must have documented undetectable viral load prior to inclusion.\n17. Chronic use of corticosteroids at doses greater than 10 mg\u002Fday of prednisone or equivalent. Patients with adrenal insufficiency of non-autoimmune etiology (e.g., previous bilateral adrenalectomy) may be included if they are clinically compensated with 10 mg\u002Fday of prednisone or equivalent or less.",{"count":157,"type":21},28,[159],"PHASE2","The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.\n\nThe study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and treatment will last for up to 12 months. The study will assess objective response, progression-free survival, and biomarkers such as PD-L1, ctDNA, and microvesicles, in a multicenter collaborative effort to provide innovative therapeutic options for this underrepresented population",[162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202],"Urachal Cancer","Parathyroid Carcinoma","Fibrolamellar Carcinoma","Angiosarcoma","Secretory Carcinoma of Breast","Anal Neoplasms","Metaplastic Breast Carcinoma","Translocation Renal Cell Carcinoma","Carcinosarcoma","Small Intestine Neoplasms","Cholangiocarcinoma","Sertoli-Leydig Cell Tumor","Adenoid Cystic Carcinoma","Mesothelioma","Neuroblastoma","Adrenal Gland Neoplasms","Penile Neoplasms","Apocrine Carcinoma","Fibrosarcoma","Cancer of Unknown Primary","Hemangioblastoma","Thyroid Neoplasms","Hepatoblastoma","Fallopian Tube Neoplasms","Leiomyosarcoma","Vaginal Neoplasms","Neurofibrosarcoma","Gallbladder Neoplasms","Osteosarcoma","Biliary Tract Neoplasms","Clear Cell Endometrial Cancer","Yolk Sac Tumor","Vulvar Neoplasms","Kaposi Sarcoma","Ovarian Epithelial Cancer","Soft Tissue Sarcoma","Urethral Neoplasms","Granulosa Cell Tumor","Primitive Neuroectodermal Tumor","Neuroendocrine Tumors","Trophoblastic Tumor",[204,163,205,164,165,206,207,168,208,170,209,172,210,211,212,213,175,176,214,215,179,180,181,182,216,184,217,186,218,188,219,190,220,192,193,221,222,195,196,197,223,199,174,200,201,202],"Urachal Adenocarcinoma","Nasopharyngeal Epithelial Tumors","Secretory Breast Carcinoma","Anal Cancer","Chromophobe Renal Carcinoma","Small Intestine Cancer","Sertoli-Leydig Cell Tumors","Non-Squamous Cervical Neoplasm","Tracheal Epithelial Tumors","Non-Adenoid Cystic Salivary Tumors","Adrenal Neoplasm","Penile Cancer","Thyroid Cancer","Fallopian Tube Cancer","Vaginal Cancer","Gallbladder Cancer","Biliary Tract Cancer","Non-Squamous Bladder Cancer","Vulvar Cancer","Urethral Cancer","2026-04-10",{"date":226,"type":37},"2026-04-15",{"date":228,"type":37},"2024-07-16",{"date":230,"type":21},"2028-05",{"name":43,"class":44},8,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":251,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":45},"100565292","phase-2-dynamic-ctdna-assessment-in-cervical-and-anal-canal-tumors-optimizing-follow-up-and-clinical-outcomes-100565292","NCT06640283","Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes","Dynamic Assessment of ctDNA in Patients With Cervical and Anal Canal Tumors to Optimize Follow-up and Clinical Outcomes in the Brazilian Unified Health System (SUS)","ANA","Inclusion Criteria:\n\n1. Histological diagnosis of anal canal or cervical cancer.\n2. Documented presence of HPV.\n3. Locally confined or locally advanced disease, defined as:\n\n   1. Anal canal carcinoma stage I to III, according to American Joint Committee on Cancer (AJCC) 8th edition;\n   2. Cervical carcinoma stage I B2 to IV A, according to AJCC 8th edition.\n4. Indication for definitive treatment with radiotherapy, with or without concomitant chemotherapy.\n5. Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) 0 - 1.\n6. Age ≥ 18 years.\n7. Signing of the Informed Consent Form (ICF).\n8. HIV-positive patients may be included if Cluster of Differentiation 4(CD4) count is greater than or equal to 200.\n9. Patients may participate in other concurrent studies, as long as they do not involve interventions related to the treatment of the underlying cancer.\n\nExclusion Criteria:\n\n1. Patients with unequivocal distant metastasis at diagnosis.\n2. For participants with positive ctDNA after treatment, those candidates for participation in Phase II will be excluded if there is unequivocal radiological progression in the first imaging exam after the completion of radiotherapy (with or without chemotherapy) or routine indication for salvage surgery immediately after the conclusion of definitive treatment.\n3. Need for recurrent blood transfusions, such as weekly frequency.\n4. Another uncontrolled disease representing a life risk, as determined by medical judgment.\n5. Personal history of another active invasive malignant neoplasm in the last 5 years, except for non-melanoma skin carcinomas and in situ carcinomas.\n6. Pregnant individuals.\n7. Active opportunistic infection or disease.\n8. History of autoimmune diseases.",{"count":242,"type":21},150,[159],"After definitive radiotherapy (RT) treatment (with or without chemotherapy), cervical and anal canal neoplasms frequently exhibit disease persistence or recurrence. Due to the local inflammatory process post-treatment, response assessment by imaging (current gold standard) is limited, often necessitating multiple follow-ups and repeated invasive biopsies. Conventional follow-up is complex and costly, requiring equipment from secondary and tertiary services, trained radiologists, and patient exposure to radiation and contrast.\n\nIn this context of human papillomavirus(HPV)-related neoplasms, recent studies have demonstrated the role of ctDNA (circulating tumor DNA) in assessing the risk of recurrence or disease progression, providing a rationale for using the tool in two fronts:\n\n* Optimizing follow-up based on serial monitoring of ctDNA;\n* Selecting patients with positive ctDNA after RT, who are at high risk of recurrence, for treatment intensification.\n\nMonitoring with ctDNA as a standalone follow-up tool in cases evolving with negative ctDNA after RT has the potential to replace imaging exams, being a minimally invasive test performed on a peripheral blood sample. Currently, ctDNA testing has expensive methodologies not available in the Unified Health System (SUS). This project aims to develop a methodology for ctDNA evaluation focused on HPV ctDNA research that is low-cost and executable in SUS, as well to assess the accuracy of this test in the population with HPV-related tumors.\n\nAdditionally, we will evaluate whether the early introduction of immunotherapy in patients with positive ctDNA after definitive treatment can increase cure rates. Immunotherapy already has a well-defined role in the treatment of metastatic HPV-related neoplasms. Recently, the use of anti-programmed death-1 (anti-PD1) has also shown benefits in patients with locally advanced cervical cancer with a high risk of recurrence who are candidates for chemoradiotherapy (CRT). Therefore, its use focused on HPV-related tumors, as well as a better understanding of which patients benefit from this strategy, warrants further investigation.",[246,247,248,249,250],"HPV-Related Carcinoma","Uterine Cervical Cancer","Anal Canal Cancer","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Cervical Carcinoma",[252,253,254,255,256,257,258],"HPV","ctDNA","Cervical tumors","Anal canal tumors","Molecular diagnosis","Diagnostic test","Biomarkers","2025-12-18",{"date":261,"type":37},"2025-12-24",{"date":263,"type":37},"2025-03-14",{"date":265,"type":21},"2027-01",{"name":43,"class":44},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":288,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":305,"locationsCount":45},"100591303","neurolytic-block-techniques-in-abdominal-visceral-cancer-pain-100591303","NCT06978673","Neurolytic Block Techniques In Abdominal Visceral Cancer Pain","Comparison of Neurolytic Block Techniques for the Treatment of Abdominal Visceral Pain and Their Influence On The Quality of Life of Patients With Cancer","CONCERN","Inclusion Criteria:\n\nPatients aged 18 years or older Presence of localized visceral pain in the upper abdomen originating from cancer of the stomach, duodenum, distal esophagus, ascending or transverse colon, liver, biliary tract, or pancreas\n\nIneffectiveness of analgesic treatment with third-step opioids according to the WHO analgesic ladder, including:\n\nOpioids (≥ 60 mg\u002Fday of morphine equivalents) Antidepressants (tricyclic or dual-action), at any dosage Gabapentinoids, at any dosage Presence of side effects from analgesics that are difficult to manage with medication\n\nExclusion Criteria:\n\nPresence of ascites Presence of deep vein thrombosis Presence of hepatic failure: Child-Pugh class B or C Presence of renal failure: estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² Use of any anticoagulant medication\n\nClinical coagulation disorder, defined as:\n\nINR \\> 1.5 Prothrombin activity \\\u003C 70% or prothrombin time \\> 13.5 seconds aPTT \\> 40 seconds Cardiovascular failure: NYHA class III",{"count":276,"type":21},64,[24],"The neurolytic blocks of sympathetic chains are commonly used for the treatment of cancer-related pain. This study aims to compare celiac plexus neurolysis and splanchnic nerve neurolysis for the treatment of abdominal visceral pain and its influence on the quality of life of patients with cancer.",[280,281,282,283,284,285,286,287],"Cancer, Malignant Tumors","Abdominal Cancer","Cancer Pain","Visceral Pain","Cancer-related Pain","Pain Management","Celiac Ganglia","Sympathetic Ganglia",[289,290,291,292,293,294,295,296,297,298,299],"cancer pain","visceral pain","abdominal cancer","cancer","abdominal pain","cancer-related pain","pain management","neurolytic block","splanchnic nerve block","celiac plexus block","sympathetic neurolysis","2025-05-30",{"date":302,"type":37},"2025-06-03",{"date":300,"type":21},{"date":41,"type":21},{"name":43,"class":44},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":321,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":45},"100591580","phase-2-oral-arsenic-with-atra-for-newly-diagnosed-patients-with-acute-promyelocytic-leukemia-100591580","NCT06982274","Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia","Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL","IC-APL2020","Inclusion Criteria:\n\n* Informed consent\n* New diagnosis of APL by cytomorphology, confirmed for molecular analysis\n* Age ≥18 and ≤75 years\n* Serum total bilirubin ≤ 3.0 mg\u002Fdl (≤ 51 μmol\u002Fl)\n* Serum creatinine ≤ 3.0 mg\u002Fdl (≤ 260 μmol\u002Fl)\n* Women must meet at least one of the following criteria to be eligible for inclusion in the study: Postmenopausal (12 months of amenorrhea or 6 months of amenorrhea with serum FSH \\> 40 U\u002Fml); After undergoing hysterectomy or bilateral oophorectomy; Continuous and correct use of a contraceptive method with a Pearl Index \\\u003C1% (e.g., implants, oral contraceptives, intrauterine devices); Sexual abstinence; Vasectomy of sexual partner.\n\nExclusion Criteria:\n\n* High-risk patients who are not eligible for chemotherapy according to the judgment of the treating physician;\n* Age \\\u003C18 or \\>75 years\n* Other active malignancy at the time of study entry\n* Lack of diagnostic confirmation at the genetic level\n* Significant arrhythmias, ECG abnormalities, or neuropathy: Congenital long QT syndrome; History or presence of significant ventricular or atrial tachyarrhythmia; Clinically significant resting bradycardia (\\\u003C50 beats per minute); QTc \\> 500 ms on ECG screening for both sexes; Right bundle branch block with left anterior hemiblock or bifascicular block\n* High-risk patients with other cardiac contraindications for intensive chemotherapy (LVEF \\\u003C 50%)\n* Uncontrolled and potentially fatal infections\n* Severe uncontrolled pulmonary or cardiac disease\n* Severe hepatic or renal dysfunction\n* Known HIV and\u002For hepatitis C infection\n* Pregnant or breastfeeding women\n* Allergy to the study drug or excipients in the study medication\n* Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or the assessment of study outcomes\n* Use of other investigational drugs at the time of enrollment or within 30 days before study entry.","75 Years",{"count":316,"type":21},115,[159],"It is a non-randomized, multicenter, prospective study, aiming to treat patients with newly diagnosed acute promyelocytic leukemia with a combination of oral arsenic and atra, with low dose chemotherapy for those with high-risk disease (white blood cell count above 10x10a9\u002FL). The primary objective is to assess the 2-year overall survival (OS) in these patients, comparing with the historical control group of patients treated with ATRA\u002Fchemotherapy according to the IC-APL 2006 protocol.",[320],"Acute Promyelocytic Leukemia (APL)",[322,323,324,325],"Acute promyelocytic leukemia","Oral arsenic","Survival","All trans-retinoic acid","2025-05-26",{"date":300,"type":37},{"date":329,"type":37},"2023-10-20",{"date":331,"type":21},"2029-11",{"name":43,"class":44},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":17,"minAge":340,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":349,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":45},"100518747","phase-2-bortezomib-based-regimen-for-refractory-or-relapsed-acute-lymphoblastic-leukemia-100518747","NCT06034561","Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia","Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia in Adults","Inclusion Criteria:\n\n* Patients between 16 and 60 years-old with refractory or relapsed ALL (≥1% of anomalous blasts by flow cytometry in bone marrow or peripheral blood) after one or two lines of therapy, regardless of their phenotype or baseline genetic alteration;\n* Patients are eligible after allogeneic HSCT as long as patients are not actively being treated for graft-versus-host-disease (GvHD).\n\nExclusion Criteria:\n\n* Burkitt leukemia;\n* Prior myeloproliferative disease;\n* Drug allergies;\n* Eastern Cooperative Oncology Group (ECOG) scale \\>2;\n* Total bilirubin\\>2x upper limit of normal (ULN);\n* Transaminases\\>5x ULN;\n* Creatinine\\>2,5 mg\u002Fdl;\n* Active uncontrolled infection;\n* History of asparaginase-induced pancreatitis;\n* Prior exposure to bortezomib;\n* Heart failure New York Heart Association (NYHA) Class III or IV;\n* Patients with more than 400mg\u002Fm2 lifetime exposure of anthracycline;\n* Severe psychiatric disorder which prevents adequate compliance;\n* Refusal to participate in the study.","16 Years","60 Years",{"count":343,"type":21},50,[159],"This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed\u002Frefractory ALL.",[347,348],"Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission",[350,351,352,353,354],"Acute lymphoblastic leukemia","Bortezomib","Salvage therapy","Bridge therapy","Response rate","2025-05-13",{"date":357,"type":37},"2025-05-16",{"date":359,"type":37},"2024-04-01",{"date":361,"type":21},"2029-08",{"name":43,"class":44},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":17,"minAge":340,"maxAge":371,"enrollmentInfo":372,"targetDuration":374,"studyType":113,"phases":4,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":45},"100512997","adult-acute-lymphoblastic-leukemia-treated-with-pediatric-regimen-in-brazil-100512997","NCT05959720","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study","BRALLA","Inclusion Criteria: Patients between 16 and 50 years-old with newly diagnosed ALL, negative for Philadelphia chromosome not previously treated (except for hydroxyurea, corticosteroids, or intrathecal chemotherapy) with 20% or more lymphoblasts in bone marrow or peripheral blood.\n\nExclusion Criteria:\n\n* Burkitt leukemia\n* Prior myeloproliferative disease\n* Philadelphia chromosome positivity through whichever methodology (RT-PCR, FISH, or conventional karyotype)\n* ECOG\\>2 (appendix 3)\n* Total bilirubin\\>2x upper limit of normal (ULN)\n* Transaminases\\>5x ULN\n* Creatinine\\>2,5 mg\u002Fdl\n* Positive serology for HIV or HTLV\n* Heart failure NYHA Class III or IV (appendix 4)\n* Severe psychiatric disorder which prevents adequate compliance\n* Prior treatment with intravenous chemotherapy\n* Refusal to participate in the study\n* Down syndrome","50 Years",{"count":373,"type":21},180,"2 Years","In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic\u002Ffollow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.",[377,378,379,380],"Acute Lymphoid Leukemia","Minimal Residual Disease","Gene Abnormality","Chemotherapeutic Toxicity","2025-05-03",{"date":383,"type":37},"2025-05-07",{"date":385,"type":37},"2023-09-05",{"date":387,"type":21},"2030-06",{"name":43,"class":44},{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":45},"100521498","comparative-study-between-fc-sems-and-pc-sems-in-the-palliation-of-dysphagia-due-to-malignant-neoplasm-of-esophagus-100521498","NCT06070376","Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.","Comparative Study Between Fully Covered Esophageal Prosthesis (FC-SEMS) and Partially Covered Esophageal Prosthesis (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.","Inclusion Criteria:\n\n* Patients with advanced malignant neoplasm of the esophagus, whether or not undergoing chemotherapy or radiotherapy;\n* Dysphagia score greater than 2 or presence of malignant esophagorespiratory fistula;\n* Indication of palliation of dysphagia through the placement of esophageal prostheses in a multidisciplinary meeting.\n\nExclusion Criteria:\n\n* Patients under 18 years;\n* Extraesophageal neoplasms;\n* Lesions with longitudinal extension less than 30 mm;\n* Previous treatment with esophageal prosthesis;\n* Tumors easily transposed to standard endoscope (9.8mm).",{"count":397,"type":21},34,[24],"Esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. The main symptom of esophageal cancer is dysphagia, associated or not with weight loss. Unfortunately, due to asymptomatic presentation in the early stages, more than half of patients are diagnosed in advanced stages of the disease, becoming ineligible for treatment with curative intent. In this sense, chemotherapy and radiotherapy are the pillars of palliative treatment, often regressing the injury and improving symptoms. However, some patients persist with dysphagia. In this scenario, esophageal prostheses are one of the main tools in the palliative treatment of esophageal cancer dysphagia, obtaining rapid and lasting relief of dysphagia. This study aims to compare fully covered (FC-SEMS) and partially covered (PC-SEMS) esophageal prostheses in this context, evaluating the number of reinterventions in each group, as well as the occurrence of adverse events. However, it is expected that with the data obtained it is possible to develop clearer and more effective protocols in the palliation of malignant dysphagia of esophageal stenosis.",[401,402],"Esophageal Neoplasms","Dysphagia",[401,404,405],"Palliation of dysphagia","Esophageal stent","2025-04-29",{"date":408,"type":37},"2025-05-01",{"date":410,"type":37},"2023-06-26",{"date":412,"type":21},"2026-08-26",{"name":43,"class":44},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":428,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":45},"100522083","comparison-of-04-hyaluronic-acid-solution-versus-hydroxyethylamide-solution-in-submucosal-endoscopic-resections-100522083","NCT06077981","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections of Superficial Malignant Esophageal Neoplasms: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Superficial esophageal adenocarcinoma or squamous cell carcinoma with indication of ESD after discussion in a multidisciplinary oncological board\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Residual or recurrent esophageal lesions\n* Ulcerated esophageal lesions\n* Patients with severe cardiovascular, kidney or liver disease\n* History of hypersensitivity to hyaluronic acid\n* Pregnant or lactating women",{"count":422,"type":21},30,[24],"This is a randomized, single-center clinical trial that will compare the efficacy of two substances used in the submucosal cushion formation stage of endoscopic submucosal resections of early esophageal malignant neoplasms. Such substances are hyaluronic acid in the form of TS-905 Blue Eyeₒ and hydroxyethylamide (Voluven®).",[401,426,427],"Endoscopic Mucosal Resection","Hyaluronic Acid",[401,426,427],{"date":408,"type":37},{"date":431,"type":37},"2023-06-19",{"date":433,"type":21},"2026-04-13",{"name":43,"class":44},{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":22,"phases":444,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":457,"leadSponsor":459,"locationsCount":45},"100584306","phase-2-efficacy-of-adding-oral-amisulpride-to-dual-prophylaxis-for-postoperative-nausea-and-vomiting-in-patients-at-high-risk-for-nausea-and-vomiting-undergoing-gynecological-surgery-100584306","NCT06887621","Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery","Patients at High Risk for Postoperative Nausea and Vomiting Undergoing Gynecological Surgery: Efficacy of Oral Amisulpride in Combination With Intravenous Ondansetron and Dexamethasone - a Parallel-group Randomized Trial","Inclusion Criteria:\n\n* Laparoscopic hysterectomy to treat benign conditions.\n* High risk for PONV according to the Apfel Score: scores 3 or 4.\n* American Society of Anesthesiology (ASA) physical status: 1 or 2.\n\nExclusion Criteria:\n\n* Cognitive or psychiatric conditions impairing consent or compliance.\n* Incapability of using the mobile app MyCapp for data collection.\n* History of allergy or sensibility to any medication included in the protocol: amisulpride, dexamethasone, ondansetron, fentanyl, midazolam, bupivacaine, morphine, propofol, rocuronium, sevoflurane, ephedrine, metaraminol, remifentanil, metamizole, ketoprofen, sugammadex, dimenhydrinate, pyridoxine hydrochloride, tramadol, dimethicone.\n* Inability to swallow medications.\n* Current use of typical or atypical antipsychotic medications.\n* Gestation or lactation.\n* Clinically significant cardiac arrhythmia or long QT syndrome documented.\n* Hypokalemia (K+ \\\u003C 3.5 mmol\u002FL)\n* Prolactin-dependent tumors.\n* Pheochromocytoma.\n* Parkinson's disease.\n* Nausea or vomiting in the 24 hours before surgery.\n* Therapeutic use of antiemetics, including corticosteroids.\n* Emetogenic oncological therapy (above 10% probability of causing vomiting) in the 2 weeks before surgery.\n* Persistent pre-operative hypotension on the day of surgery, defined as systolic blood pressure \\\u003C 100 mmHg on at least 2 consecutive measurements.\n* Mechanical ventilation plan or need for a naso\u002Forogastric tube after surgery.\n* Intestinal endometriosis",{"count":443,"type":21},276,[159],"Amisulpride is a potent antagonist of dopamine D2 and D3 receptors, both implicated in the emetic response when activated. It is currently used intravenously for the prevention of chemotherapy-induced and postoperative nausea and vomiting (PONV), but this route has a short half-life time of 4 to 5 hours, could be expensive, causes infusion-related pain, and is not available in Brazil. Some of these limitations could be overcome by the preemptive use of an oral formulation. At present, there are no data regarding the use of oral amisulpride for PONV, which is an affordable and painless option with half-life time of 12 hours. We propose a quadruple-blind clinical trial involving patients undergoing gynecological surgery aged 18 years and older, and assessed as being at high risk for PONV according to the Apfel Score (score 3 or 4). The primary outcome of this study is to evaluate complete response to PONV up to 24h, comparing the efficacy of adding 50 mg oral amisulpride as a third antiemetic agent to the standard institutional protocol at the Hospital da Mulher of São Paulo (IV dexamethasone 10 mg + IV ondansetron 4 mg) for laparoscopic surgeries. Secondary outcomes will evaluate (1) nausea, (2) vomiting, (3) nausea and vomiting, (4) use of rescue treatment, (5) overall adverse events, and (6) adverse events.",[447],"Post Operative Nausea and Vomiting (PONV)",[449,450,451,452],"Amisulpride","Postoperative Nausea and Vomiting","Laparoscopy","Gynecologic Surgical Procedures","2025-04-10",{"date":455,"type":37},"2025-04-13",{"date":453,"type":37},{"date":458,"type":21},"2027-03-31",{"name":43,"class":44},{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":4},"100550037","study-to-compare-two-partial-nephrectomy-techniques-for-renal-tumors-robot-assisted-vs-videolaparoscopic-100550037","NCT06441851","Study to Compare Two Partial Nephrectomy Techniques for Renal Tumors: Robot-assisted vs Videolaparoscopic","Randomized Clinical Trial to Compare Two Partial Nephrectomy Techniques for Renal Tumors: Robot-assisted vs Videolaparoscopic","VPN x RANP","Inclusion Criteria:\n\n* Patients between 18 and 99 years old;\n* Patients with non-metastatic renal cancer (confirmed by pre operatory TC);\n* Patients eligible for videolaparoscopic partial nephrectomy;\n* Patients who signed study informed consent form\n\nExclusion Criteria:\n\n* Pregnant patients;\n* Patients with concomitant indications with nephrectomy;\n* Patients with a clinical condition that contraindicates nephrectomy;\n* Patients with a clinical condition that contraindicates robot-assisted surgeries (determined by urology team);\n* Patients with previous surgeries that contraindicates robot-assisted surgeries (determined by urology team);","99 Years",{"count":343,"type":21},[24],"Randomized, open-label clinical trial to compare renal volumetry pre and post operative in patients undergoing two types of partial nephrectomy techniques for renal tumors: robot-assisted vs videolaparoscopic.",[473],"Renal Cancer",[475,476,477,478,479],"Renal cancer","Nephrectomy","Partial nephrectomy","Videolaparoscopic partial nephrectomy","Robot-assisted partial nephrectomy","2024-06-02",{"date":482,"type":37},"2024-06-04",{"date":484,"type":21},"2024-07",{"date":486,"type":21},"2027-07",{"name":43,"class":44},{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":497,"briefSummary":498,"conditions":499,"keywords":502,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":45},"100512611","supercharged-tram-evaluation-in-cervical-esophagogastroplasty-after-esophagectomy-100512611","NCT05954702","Supercharged TRAM Evaluation in Cervical Esophagogastroplasty After Esophagectomy","Supercharged","Inclusion Criteria:\n\n* Diagnosis of esophageal malignancy cancer;\n* Ability to understand and collaborate during treatment;\n\nExclusion Criteria:\n\n* Previous gastrectomy;\n* Previous abdominal surgery with risk of altering stomach vascularization;\n* Previous head and neck surgery with risk of alteration of cervical vessels.",{"count":496,"type":21},60,[24],"Esophagectomy has high rates of morbidity and mortality, in many cases due to esophagus reconstruction. Anastomotic leakage and fistula are the main esophagectomy complications. Many studies underwent to investigate the cause for anastomotic leakage after esophagectomy, however none of them conclude it is related to surgery or suture technique. However, it seems to be triggered by the ischemia caused after stomach mobilization to esophagus reconstruction, or even tension in the anastomosis.\n\nConsidering the post esophagectomy with gastroplasty high morbidity and mortality rates, strategies to create a new vascularization source and decrease anastomotic leakage rates is important. In this study researchers will evaluate whether a TRAM flap transfer supercharged is effective on decrease morbidity related to anastomosis ischemia in patients undergoing esophagectomy.",[500,501],"Esophagus Cancer","Carcinoma Esophagus",[503,504,493],"Esophagectomy","Esophagogastroplasty","2023-10-13",{"date":507,"type":37},"2023-10-16",{"date":509,"type":37},"2023-07-21",{"date":511,"type":21},"2026-10",{"name":43,"class":44},{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":522,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":45},"100515811","prospective-cohort-of-single-dose-radiotherapy-for-painful-bone-lesions-in-multiple-myeloma-100515811","NCT05996367","Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma","Prospective Cohort Assessing the Impact of Single-dose Radiotherapy in the Treatment of Painful Bone Lesions in Patients With Multiple Myeloma","Inclusion Criteria:\n\n* Biopsy of plasma cell neoplasm with bone lesion treatable with radiotherapy;\n* Age between 18 and 85 years old;\n* Performance on the ECOG scale less than or equal to 2.\n* Not using systemic therapies for 4 weeks OR being on maintenance therapy with the same drug for at least 4 weeks before radiotherapy.\n\nExclusion Criteria:\n\n* Refusing to sign or inability to understand the consent term;\n* Pain less than 2\u002F10 on the numeric pain rating scale;\n* Change in systemic treatment scheme, including use of bone metabolism modulation drugs, up to 4 weeks before radiotherapy treatment;\n* Technical incapacity for the treatment, including, but not limited to, weight greater than 115Kg, inability to abduct the limb to be treated in appendicular bones, intolerable pain to remain in the treatment position;\n* Previous cancer and previous oncological treatments;\n* Previous autoimmune diseases, even if controlled;\n* Current pregnancy.","85 Years",{"count":343,"type":21},[24],"Multiple myeloma is a plasma cell neoplasm that can cause painful bone lesions. The main treatment for these lesions and pain control is radiotherapy, usually in daily fractions. In 2017, a phase III study proved the effectiveness of using a single dose of 8 Gy, but without description of several important oncological outcomes. This is a single-arm prospective cohort study. This study aims to describe these outcomes, including retreatment rate and bone events. Also, as secondary objectives, describe the quality of life and use of analgesic medications in this population.",[525],"Multiple Myeloma",[527,528,529],"Multiple myeloma","Palliative care","Radiotherapy","2023-08-09",{"date":532,"type":37},"2023-08-18",{"date":534,"type":37},"2023-07-31",{"date":536,"type":21},"2029-07-31",{"name":43,"class":44},{"id":539,"slug":540,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":45},"100416099","phase-2-local-therapy-for-erpr-positive-oligometastatic-breast-cancer-100416099","NCT04698252","Local Therapy for ER\u002FPR-positive Oligometastatic Breast Cancer","Local Therapy for Hormone Receptor-positive Oligometastatic Breast Cancer - a Phase II Randomized Trial","LARA","Inclusion Criteria:\n\n* Female sex\n* ≥ 18 years of age\n* Histologically confirmed invasive breast cancer, with oligometastatic disease defined as one of the following criteria: 1) One to four bone lesions; 2) One to four lung and\u002F or hepatic lesions; 3) Distant metastasis limited to ipsilateral cervical lymph nodes; 4) Distant metastasis limited to contralateral axillary lymph nodes\n* Oligometastatic sites amenable to treatment with a local therapy modality, including surgical resection, stereotactic radiotherapy, or radiofrequency ablation\n* Estrogen receptor-positive and\u002F or progesterone receptor-positive breast cancer\n* Partial response or stable disease after at least six months of systemic therapy for breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Measurable or non-measuble disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Life expectancy of at least 12 weeks\n* For women in childbearing age, negative pregnancy test until 21 days before the date of study enrollment.\n* Signed informed consent form\n* Disposition and aptitude to fulfill the study protocol during the study duration\n\nExclusion Criteria:\n\n* HER2-positive breast cancer\n* Progressive disease during the last systemic treatment received for metastatic disease\n* Previous local therapy for distant metastasis\n* Current or previous history of severe diseases, such as clinically relevant heart failure, acute myocardium infarction in the last six months, chronic obstructive lung disease, HIV infection, chronic active hepatitis B or C infection, current serious uncontrolled infections or other severe diseases that may impact patients' expected survival)\n* Current or previous history of other invasive malignancy within the last five years, excluding non-melanoma skin cancer",{"count":547,"type":21},74,[159],"Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER\u002FPR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.",[89],[552,553,554,529,555],"Oligometastasis","Hormone Receptor Positive","Surgery","Radiofrequency ablation","2022-08-05",{"date":558,"type":37},"2022-08-08",{"date":560,"type":37},"2021-04-01",{"date":562,"type":21},"2031-04-01",{"name":43,"class":44},{"id":565,"slug":566,"hasResults":11,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":314,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":45},"100349135","phase-2-neoadjuvant-folfirinox-in-the-treatment-of-locally-advanced-gastric-cancer-100349135","NCT03825861","Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer","FOLFIRINOX","Inclusion Criteria:\n\n* Histological diagnosis of gastric adenocarcinoma that is amenable to surgical resection at diagnosis, with locally advanced disease criteria for clinical evaluation (T3 tumors, T4 tumors and \u002F or regional lymph node involvement).\n* Absence of metastatic disease at a distance (computerized tomography, diagnostic laparoscopy and peritoneal lavage).\n* Age 18-75 years.\n* Clinical functionality by the ECOG scale between 0 and 1.\n* Preserved renal function (creatinine clearance greater than 50 mL \u002F min).\n* Signature of Informed Consent Form\n\nExclusion Criteria:\n\n* Active neoplasm of another primary site other than non-melanoma skin carcinoma.\n* Lesions of the esophagogastric transition\n* Unresectable lesions by computed tomography and \u002F or diagnostic laparoscopy.\n* Obstructive tumors (acute intestinal occlusion or subocclusion).\n* Tumors with signs of significant or persistent bleeding.\n* Carcinoma in situ.\n* Different histological type of adenocarcinoma.\n* Gastric stump tumors.\n* Previous chemotherapeutic or radiotherapy treatment.\n* Current pregnancy or breastfeeding.\n* Total bilirubin above 1.5mg \u002F dL.\n* Hepatic transaminases greater than 1.5 times the upper limit of normality.\n* Decompensated and \u002F or symptomatic cardiomyopathy: congestive heart failure with functional class greater than 2 by the New York Heart Association; active coronary disease; uncontrolled cardiac arrhythmia; history of acute myocardial infarction in the last 6 months.\n* Psychological, familial, social or even geographical condition that potentially hinders adherence to the study protocol and the pre-established follow-up.\n* Current or previous psychiatric or neurological diagnosis that is decompensated, compromises the cognition, functionality or adherence to the proposed treatment.\n* Other comorbidities that are decompensated at the time of treatment.\n* Pregnant or breastfeeding women.",{"count":572,"type":21},27,[159],"Phase II single-arm study designed to evaluate the efficacy and safety of preoperative chemotherapy with FOLFIRINOX regimen. The investigators will include 27 patients with resectable locally advanced gastric cancer. They will receive preoperative chemotherapy with FOLFIRINOX regimen by long-term catheter every 14 days for 8 cycles accounting for a total of 4 months of systemic treatment. In the period between 4 and 8 weeks of the last cycle, restaging tests will be performed and if there is no metastatic progression of disease, the patient will undergo surgical treatment with curative intention. The objective is to evaluate whether preoperative treatment with FOLFIRINOX regimen involving continuous infusion and bolus infusion of 5-fluoruracil, irinotecan bolus and oxaliplatin bolus is effective and safe in the neoadjuvant treatment of locally advanced gastric cancer.\n\nThe planned recruitment period is 48 months (4 years). There will be a total of 4 months of preoperative chemotherapy. In case of limiting toxicity or disease progression, chemotherapy will be suspended and patients may undergo resection of the primary neoplasia at the discretion of the surgical team of the institution. Patients will be followed for 5 years after entry of the last participant in the protocol for OS and PFS evaluation. The end of the study will occur when the last participant completes their last follow-up visit, which should occur no later than 60 months after enrollment in the study.",[576],"Gastric Cancer",[576,569],"2020-11-09",{"date":580,"type":37},"2020-11-10",{"date":582,"type":37},"2017-02-23",{"date":584,"type":21},"2026-12-30",{"name":43,"class":44},""]